Dynavax Technologies Corp. (NASDAQ:DVAX)’s share price traded up 5% during trading on Wednesday . The stock traded as high as $15.59 and last traded at $15.52, with a volume of 271,936 shares traded. The stock had previously closed at $14.78.

Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Dynavax Technologies Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, April 19th. JPMorgan Chase & Co. downgraded shares of Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $29.00 to $22.00 in a research report on Wednesday, April 27th. Royal Bank Of Canada downgraded shares of Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $48.00 to $17.00 in a research report on Wednesday, April 27th. Finally, Cowen and Company reissued a “buy” rating and set a $60.00 target price on shares of Dynavax Technologies Corp. in a research report on Thursday, April 28th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $32.20.

The stock’s market capitalization is $608.61 million. The stock’s 50 day moving average price is $14.80 and its 200-day moving average price is $17.93.

Dynavax Technologies Corp. (NASDAQ:DVAX) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.07. The business had revenue of $942 million for the quarter, compared to analysts’ expectations of $627 million. On average, equities analysts predict that Dynavax Technologies Corp. will post ($2.90) EPS for the current fiscal year.

In other Dynavax Technologies Corp. news, CEO Eddie Gray acquired 2,750 shares of the business’s stock in a transaction on Friday, May 20th. The stock was purchased at an average price of $15.57 per share, with a total value of $42,817.50. Following the acquisition, the chief executive officer now directly owns 5,050 shares of the company’s stock, valued at approximately $78,628.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Several hedge funds have recently modified their holdings of the company. Trexquant Investment LP increased its stake in shares of Dynavax Technologies Corp. by 14.5% in the fourth quarter. Trexquant Investment LP now owns 70,200 shares of the biopharmaceutical company’s stock worth $1,696,000 after buying an additional 8,911 shares during the period. California State Teachers Retirement System increased its stake in shares of Dynavax Technologies Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,895 shares of the biopharmaceutical company’s stock worth $1,640,000 after buying an additional 1,177 shares during the period. Finally, Swiss National Bank increased its stake in shares of Dynavax Technologies Corp. by 5.7% in the fourth quarter. Swiss National Bank now owns 48,528 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 2,600 shares during the period.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.